Från ett spretigt bygge till en skalbar SaaS-maskin – Carasents historik och tidigare svaga sentiment har skapat en omotiverad rabatt i värd...
Redeye retains its positive view of Carasent following the Q4 report.
Redeye comments on Carasent’s Q4 report, showing slightly lower organic ARR growth yet solid scalability.
Redeye comments on decision by the VGR Regional Board regarding Millennium and the modular alternative.
Redeye comments on the news from VGR regarding its future healthcare information environment.
Redeye retains its positive view of Carasent following the Q3 report.
Redeye sees a solid Q3 report from Carasent with slightly lower ARR growth but better cost control than expected.
Redeye updates its Base Case and forecasts following the Q2 report, showing solid underlying business momentum despite the lowered 2025 targ...
Redeye comments on Carasent’s Q2 report, showing a more positive outlook than the preliminary figures suggested.
Redeye comments on Carasent’s preliminary Q2 figures, the revised 2025 targets, and the new mid-term targets.
Redeye retains its positive view of Carasent following the Q1 report.
Redeye comments on Carasent’s Q1 report, showing solid ARR growth yet somewhat higher OPEX.
Redeye comments on Carasent’s Q4 report, showing slightly softer numbers than expected.
Redeye takes a positive view towards the acquisition of Data-AL.
Redeye retains its positive view of Carasent following a solid Q3 report showing accelerating organic growth and positive EBITDA-CAPEX – to ...
Redeye has updated its estimates for Carasent following the Q2 2024 report, which was quite undramatic.
Redeye comments on Carasent’s Q2 2024 report, which came in slightly lower on revenues.
On July 4, after trading closed on Oslo Børs, EG informed Carasent it will not proceed with an offer.
Redeye has updated its estimates for Carasent following the Q1 2024 report, which was more or less in line with our estimates, and the revis...
Redeye comments on Carasent’s Q1 2024 report and its announcement of revised financial targets.
Redeye comments on Medrave's new contract with VGR.
Redeye has updated its estimates for Carasent following the Q4 2023 report, which showed slightly stronger sales but somewhat lower margins.
Redeye comments on Carasent's Q4 2023 report, which came in in line on sales, but slightly lower on margins.
Carasent has entered into an agreement to sell the Confrere brand and customer contracts to Compodium International.
Redeye comments on ACapital Cara HoldCo AS's demand for an extraordinary general meeting.
Redeye comments on the news yesterday that Carasent’s subsidiary, Metodika EPM signed, a contract with Volvat, with an estimated annual reve...
Redeye shares its insights after Carasent’s Capital Markets Day (CMD) and revises its estimates accordingly.
Redeye has updated its estimates for Carasent following the Q3 2023 report, which was heavily influenced by a seasonality pattern that we un...
Redeye comments on Carasent's Q3 2023 report, which was heavily influenced by lower consulting revenue and seasonality effects related to th...
On September 21, Carasent announced that it would initiate a share buyback program and deliver a special dividend.
Yesterday, Carasent announced that, following a review of the company’s capital structure, its board has decided to reduce the large cash po...
Redeye comments on Finansavisen’s article this morning regarding John Fredriksen’s redemption request from Aeternum.
Carasent’s Q2 2023 report contained no big surprises.
Redeye comments on Carasent's Q2 2023 report, which showed small improvements compared to the previous quarter.
Redeye updates its estimates of Carasent after the Q1 2023 report, change of focus, and cost-savings program.
Redeye comments on Carasent's Q1 2023 report, showing a growth rate of 34% y/y and 16% organically y/y, slightly better than our estimate.
Redeye gives a brief follow-up comment on the change of focus and cost savings.
Redeye provides an initial comment on Carasent's shift in focus towards the Swedish market, citing "a larger and more attractive market" in ...
Redeye updates its estimates following Carasent’s Q4 2022 report, which showed stronger growth than what we had anticipated.
Redeye comments in Carasent's Q4 2022 report, which came in above our estimates on the ARR and net sales, but slightly below on the margin s...
Redeye updates its estimates following Carasent’s Q3 report and the acquisitions of HPI and Confrere.
Redeye comments on Carasent's Q3 report, which was partly known due to preliminary numbers released on October 17.
Redeye comments on the acquisition of HPI Health Profile Institute, a provider of software solutions for occupational healthcare and an add-...
Redeye comments on Carasent’s Q3 preliminary numbers.
Redeye comments on Carasent’s deal in Norway yesterday, taking over customer agreements from Confrere.
Redeye updates its estimates following Carasent’s Q2’22 report, which was a tad weaker than anticipated.
Redeye comments on Carasent's Q2 2022 report, which came in slightly lower than our estimates on the top line and margins.
Redeye comments on the news of Daniel Öhman being appointed as the new CEO of Carasent, following Dennis Höjer's decision to step down earli...
Redeye updates its estimates following Carasent’s Q1 report and comments on topics ranging from the heavy capex cycle to CEO Dennis Höjer’s ...
Redeye comments on Carasent’s Q1 report, which was solid albeit somewhat below our sales estimates.
Redeye updates its estimates for 2022 following the Q4 report, and comments on various subjects, ranging from organic growth, net revenue re...
Redeye comments on Carasent's Q4 report, which was slightly weaker than expected, partly due to issues stemming from the pandemic.
Carasent reported a stable quarter with good customer intake and clear signs of scalability.
Carasent's net sales were in line with Redeye's estimates, but profitability and customer intake were stronger than expected.
Yesterday, Vitruvian Partners invested NOK 420m in a private placement, making the private equity firm Carasent’s largest shareholder.
